Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

mosunetuzumab-axgb

View Patient Information
A bispecific, humanized monoclonal antibody with potential antineoplastic activity. Mosunetuzumab contains two antigen-recognition sites: one for human CD3, a T-cell surface antigen, and one for human CD20, a tumor-associated antigen (TAA) that is exclusively expressed on B cells during most stages of B-cell development and is often overexpressed in B-cell malignancies. Upon administration, mosunetuzumab binds to both T cells and CD20-expressing tumor B cells; this cross-links T cells to tumor cells, and may result in a potent cytotoxic T-lymphocyte (CTL) response against CD20-expressing tumor B cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-CD20 x anti-CD3 bispecific monoclonal antibody BTCT4465A
CD20/CD3 BiMAb BTCT4465A
mosunetuzumab
US brand name:Lunsumio
Code name:BTCT 4465A
BTCT-4465A
BTCT4465A
RG 7828
RG-7828
RG7828
RO7030816
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search